- Generic name
- Levetiracetam
- Strength
- 750 mg
- Dosage form
- Tablet
- Manufactured by
- Advanced Chemical Industries PLC
Citazar Tablet
About Citazar 750 mg Tablet
Citazar is a 750 mg tablet made by Advanced Chemical Industries PLC. It contains levetiracetam and is used as an add-on anti-epileptic medicine for certain types of seizures.
There are 34 brands of Levetiracetam listed in Bangladesh. The lowest listed price is Citazar 250 mg Tablet at ৳ 15.11 per unit.
What is Citazar 750 mg Tablet?
Citazar is a tablet manufactured by Advanced Chemical Industries PLC. It contains levetiracetam, which belongs to a group of medicines called adjunct anti-epileptic drugs. It is used together with other epilepsy medicines to treat partial-onset seizures, with or without secondary generalisation. It is also used on its own in some newly diagnosed cases. Epilepsy medicines work over time, so the doctor plans the dose and course for each person. Do not stop or change this medicine on your own; ask your doctor or pharmacist if you have questions.
Uses of Citazar
Citazar is prescribed for partial-onset seizures, which begin in one part of the brain and may or may not spread. It is used as add-on therapy alongside other epilepsy medicines. In some newly diagnosed cases, it may be used alone. The doctor decides whether it suits your type of epilepsy. Ask your doctor or pharmacist how it fits into your treatment plan.
How to use Citazar
Swallow the Citazar tablet with water as your doctor tells you. The doctor decides the dose, how often to take it, and how long the course lasts. Do not change the dose or stop the medicine on your own, because stopping suddenly can be harmful. If you miss a dose, ask your doctor or pharmacist what to do. Keep the medicine out of reach of children.
Side effects of Citazar
Common side effects include sleepiness, weakness, infection and dizziness in adults. Children may feel tired, irritable, aggressive, have a blocked nose or eat less. Call your doctor if you notice unusual bruising or bleeding, signs of infection, or a serious fall in alertness. Also seek help if you have a seizure that is different from usual, or any reaction that worries you.
Safety and precautions
Do not take Citazar if you are allergic to levetiracetam, other pyrrolidone derivatives, or any ingredient of the tablet. Tell your doctor about kidney or liver problems, because the dose may need adjusting. The medicine is not recommended in pregnancy or in women who could become pregnant and are not using contraception unless the doctor decides it is necessary. It passes into breast milk, so breastfeeding is not recommended. Ask your doctor before breastfeeding, and about driving or working with machines.
Frequently asked questions
What is Citazar used for and what kind of medicine is it?
Citazar is an adjunct anti-epileptic medicine. It is used with other medicines to treat partial-onset seizures, and sometimes alone in newly diagnosed cases. The doctor decides if it is right for your epilepsy.
What side effects should I watch for, and when should I call the doctor?
Watch for sleepiness, weakness, dizziness or infection. In children, look for tiredness, irritability or aggression. Call your doctor if you notice unusual bruising or bleeding, signs of infection, or any reaction that worries you.
Who should avoid Citazar or ask the doctor first?
Do not take it if you are allergic to levetiracetam or similar medicines. Tell your doctor if you have kidney or liver problems, are pregnant or could become pregnant, or are breastfeeding. Ask the doctor before driving or using machines.
Can I stop Citazar on my own?
No. Do not stop or change the dose without your doctor's advice. Stopping suddenly can be harmful. The doctor decides how long you need the medicine and how to stop it safely.
Also available as
100 mg/ml (Suspension)1000 mg (Tablet)250 mg (Tablet)500 mg (Tablet)
Indications
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy. ... Read more
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
- in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
Dosage & Administration
Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more: The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decrease every two to four weeks.
Pediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases, oral solution should be used.
- Monotherapy: The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.
- Add-on therapy: Oral solution is the preferred formulation for use in infants and children under the age of 6 years. For children 6 years and above, oral solution should be used for doses under 250 mg, for doses not in multiples of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. The lowest effective dose should be used. The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily. Dosing for children 50 kg or greater is the same as in adults.
- Add-on therapy: For infants aged from 1 month to less than 6 months: The oral solution is the formulation to use in infants.
Interaction
Probenecid: Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.
Methotrexate: Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.
Laxatives: There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.
Food and alcohol: The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced. No data on the interaction of levetiracetam with alcohol are available.
Contraindications
Side Effects
- Adult patients: somnolence, asthenia, infection and dizziness
- Pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability
Pregnancy & Lactation
Precautions & Warnings
Acute kidney injury: The use of levetiracetam has been very rarely associated with acute kidney injury with a time to onset ranging from a few days to several months.
Blood cell counts: Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders.
Suicide: Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known. Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.
Paediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Available data in children did not suggest an impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.
Overdose Effects
Storage Conditions
Alternative brands of Levetiracetam
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.